Insider Reported By SEC: Retrophin Inc (NASDAQ:RTRX)’s Stock Insider Deal – Steve Aselage Sells 8,200 Shares

November 23, 2016 - By Hazel Jackson

Insider Reported By SEC: Retrophin Inc (NASDAQ:RTRX)'s Stock Insider Deal   Steve Aselage Sells 8,200 Shares

Steve Aselage Insider Sell

Chief Executive Officer Steve Aselage of Retrophin Inc, unloaded some 8,200 of the Pinksheet-listed company shares having a market value near $173,160 U.S Dollars with an average of $21.1 stock price for a share. The regulatory filing shows that Steve Aselage now has ownership of precisely 0.63% of the New York-based company’s market cap (share price times the number of shares outstanding)

Retrophin Inc (NASDAQ:RTRX) Ratings Coverage

Out of 3 analysts covering Retrophin (NASDAQ:RTRX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $44 is the highest target while $25 is the lowest. The $33 average target is 53.56% above today’s ($21.49) stock price. Retrophin has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. BMO Capital Markets initiated Retrophin Inc (NASDAQ:RTRX) on Tuesday, April 12 with “Outperform” rating. The rating was downgraded by Zacks to “Buy” on Wednesday, August 12. The company was initiated on Monday, November 2 by JMP Securities.

Insitutional Activity: The institutional sentiment increased to 1.63 in Q2 2016. Its up 0.33, from 1.3 in 2016Q1. The ratio is positive, as 15 funds sold all Retrophin Inc shares owned while 29 reduced positions. 12 funds bought stakes while 45 increased positions. They now own 38.66 million shares or 4.59% more from 36.97 million shares in 2016Q1.

Blackrock, a New York-based fund reported 13,070 shares. Everpoint Asset Management Lc accumulated 550,000 shares or 0.19% of the stock. Architects Inc, a New Jersey-based fund reported 2,000 shares. Northern Trust Corp last reported 379,439 shares in the company. Comml Bank Of America Corporation De, a North Carolina-based fund reported 21,524 shares. Lombard Odier Asset Management (Usa) owns 1.08M shares or 2.34% of their US portfolio. Commercial Bank Of Ny Mellon Corp holds 522,706 shares or 0% of its portfolio. Jpmorgan Chase And Com has invested 0% of its portfolio in Retrophin Inc (NASDAQ:RTRX). Franklin Resource accumulated 0.01% or 1.10 million shares. American Intll Gru last reported 20,847 shares in the company. Blackrock Ltd Limited Liability Company holds 0% of its portfolio in Retrophin Inc (NASDAQ:RTRX) for 65,252 shares. Td Asset Mngmt Inc reported 20,900 shares or 0% of all its holdings. Moreover, Teacher Retirement Systems Of Texas has 0% invested in Retrophin Inc (NASDAQ:RTRX) for 4,434 shares. Rock Springs Capital Mgmt Ltd Partnership owns 521,400 shares or 0.69% of their US portfolio. Turner L P has 0.5% invested in the company for 90,354 shares.

Insider Transactions: Since June 1, 2016, the stock had 0 insider buys, and 2 sales for $297,343 net activity. 8,750 Retrophin Inc (NASDAQ:RTRX) shares with value of $142,059 were sold by Shih Alvin.

The stock increased 1.75% or $0.37 during the last trading session, hitting $21.49. About 465,580 shares traded hands. Retrophin Inc (NASDAQ:RTRX) has risen 37.14% since April 21, 2016 and is uptrending. It has outperformed by 31.81% the S&P500.

Retrophin, Inc. is a biopharmaceutical firm focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The company has a market cap of $807.05 million. It sells three products, including Chenodal , Cholbam (cholic acid) and Thiola (tiopronin). It currently has negative earnings. The Company’s Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

According to Zacks Investment Research, “Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company’s approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego.”

Analysts await Retrophin Inc (NASDAQ:RTRX) to report earnings on February, 23. They expect $-0.21 EPS, down 400.00% or $0.28 from last year’s $0.07 per share. After $-0.25 actual EPS reported by Retrophin Inc for the previous quarter, Wall Street now forecasts -16.00% EPS growth.

More recent Retrophin Inc (NASDAQ:RTRX) news were published by: Fool.com which released: “Why Shares of Retrophin Inc Are Soaring Today” on September 07, 2016. Also Fool.com published the news titled: “Why Retrophin Inc was Down Today” on February 10, 2016. Reuters.com‘s news article titled: “Retrophin to pay $3 million in US lawsuit over Shkreli’s tenure” with publication date: February 03, 2016 was also an interesting one.

RTRX Company Profile

Retrophin, Inc. (Retrophin), incorporated on February 7, 2008, is a biopharmaceutical company. The Firm is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Firm sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). The Company’s Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. The Company’s Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. The Company’s Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>